|drug3482||Ultrasound of the lower limbs Wiki||0.58|
|drug1792||Linagliptin 5 MG Wiki||0.58|
|drug1827||Lovenox 40 MG in 0.4 mL Prefilled Syringe Wiki||0.58|
|D044882||Glucose Metabolism Disorders NIH||0.82|
|D008661||Metabolism, Inborn Errors NIH||0.58|
|D004700||Endocrine System Diseases NIH||0.41|
There are 3 clinical trials
The coronavirus disease 2019 (COVID-19) is an emerging pandemic in 2020 caused by a novel coronavirus named SARS-CoV2. Diabetes confers a significant additional risk for COVID-19 patients. Dipeptidyl peptidase 4 (DPP-4) is a transmembrane glycoprotein expressed ubiquitously in many tissues. In addition to its effect on glucose levels, DPP-4 has various effects on the immune system and several diseases, including lung diseases. This trial aims to assess the safety and efficacy of linagliptin, a DPP-4 inhibitor, in the treatment of COVID-19. The trial will be randomized without blinding, with one are treated by insulin only for glucose balance and the other by insulin and linagliptin. The trial will assess the effects of linagliptin on different measures of COVID-19 recovery.
Description: Clinical change is defined as 2 points reduction in the World Health Organization (WHO) Ordinal Scale for Clinical Improvement of COVID-19: 0 - No clinical or virological evidence of infection; 1 - No limitation of activities; 2 - Limitation of activities; 3 - Hospitalized, no oxygen therapy; 4 - Oxygen by mask or nasal prongs; 5 - Non-invasive ventilation or high-flow oxygen; 6 - Intubation and mechanical ventilation; 7 - Ventilation + additional organ support - pressors, renal replacement therapy, extracorporeal membrane oxygenation; 8 - Death.Measure: Time to clinical change Time: 28 days
Description: Percent of patients with a 2 points reduction in the World Health Organization (WHO) Ordinal Scale for Clinical Improvement of COVID-19.Measure: Percent of patients with clinical improvement. Time: 28 days
The outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the COVID-19 (Coronavirus Disease-2019) in December 2019 has led to an unprecedented international health situation. Exceptional measures have been taken by public authorities worldwide in order to slow the spread of the virus and prevent healthcare systems from becoming overloaded. In France, a national lockdown has been established during approximately 2 months to increase social distancing and restrict population movements. Hospital routine care appointments have been cancelled, in order to reallocate medical resources towards COVID-19 units and limit contacts between patients within hospitals or waiting rooms. While the virus itself, the disease and potential treatments are currently extensively studied, little data are available on the effect of these public health decisions on the management of a chronic condition such as diabetes. The French regional CONFI-DIAB study aims at assessing the collateral impact of routine care cancellation during the national lockdown due to COVID-19 in patients with a chronic condition such as diabetes. Special attention will be given to metabolic control and access to health care. This cross-sectional study should provide information on the consequences of a global lockdown and the associated routine care cancellation on the management of diabetes, and inform future decision making in the event of a new pandemic.
Description: HbA1c levels before and after the lockdown period. A 3 months period is required between the 2 values.Measure: Compare glycated hemoglobin levels of patients with diabetes from the University Hospital of Nancy between the period preceding and following the lockdown related to the COVID-19 pandemic. Time: 6 months period prior to lockdown - 6 weeks period following the end of the lockdown
Description: Use type of diabetes, BMI, lipid profile, micro- and macro-comorbidities and usual therapies from medical recordsMeasure: Describe the clinical and biological characteristics of patients with diabetes followed in routine care at the University Hospital of Nancy Time: 6 weeks period following the end of the lockdown
Description: Use BMI, lipid profile, renal and hepatic function from medical recordsMeasure: Describe the change from baseline of biological and clinical parameters of patients with diabetes followed in routine care at the University Hospital of Nancy between the period preceding and following the lockdown. Time: 6 months period prior to lockdown - 6 weeks period following the end of the lockdown
Description: Ketosis, Ketoacidosis, severe hypoglycemia, COVID-19 infection, hospitalizationMeasure: Describe the proportion of patients who presented with one or more significant clinical event during the lockdown. Time: 6 weeks period following the end of the lockdown
Description: Proportion of patients who forgot and/or discontinued one or several medication(s), medication involved, duration and frequency of omission/discontinuationMeasure: Describe the proportion of patients who forgot and/or discontinued one or several medication(s) during the lockdown. Time: 6 weeks period following the end of the lockdown
Description: Porportion of patients who modified their usual level of physical activity and/or their consumption of alcohol and/or tobaccoMeasure: Describe the proportion of patients who changed their lifestyle's habits during the lockdown. Time: 6 weeks period following the end of the lockdown
Description: Proportion of patients who consulted their GP, a specialist physician, pharmacist, biologist, nurse, paramedic, other healthcare professional; type of visit (regular face to face, telemedecine); method for prescription renewal; reason for delay in care; hospitalization (excluding for COVID-19)Measure: Describe healthcare consumption of patients with diabetes during the lockdown. Time: 6 weeks period following the end of the lockdown
Description: Proportion of patients who (1) was tested for SARS-CoV-2 by PCR, (2) developped COVID-19 confirmed by PCR and (3) was hospitalized due to the severity of COVID-19.Measure: Describe the proportion of patients who (1) was tested for SARS-CoV-2 by PCR, (2) developped COVID-19 confirmed by PCR and (3) was hospitalized due to the severity of COVID-19. Time: 6 weeks period following the end of the lockdown
No additional risk factors have been identified in patients with Inherited Metabolic Diseases (IMD) for contracting or presenting complications of COVID-19 compared to the general population. Yet, IMD patients have cell/tissue alterations that could constitute a potential direct or indirect target for the virus. We do not know the impact of this infection on patients suffering from MHM, nor the possible effect of specific treatment of MHM on the evolution of COVID-19. This study will collect French IMD patients having or having had COVID-19 infection. The main objective is to estimate among IMD patients contracting COVID-19 the frequency of disease aggravation or metabolic decompensation. The secondary objectives will be : a. to evaluate the incidence of COVID-19 diagnosed in a given group of IMD when the number of patients with this IMD is known (Urea Cycle Deficiency, Gaucher Disease). b. to evaluate the impact of IMD on the and severity of COVID-19 infection
Description: disease aggravation or metabolic decompensation, among MHM-infected patients with COVID-19.Measure: Frequency of MHM imbalance triggered by COVID-19 Time: at 8 weeks
Description: severity of COVID-19 infection as assessed by hospitalization; Intensive Care Unit, deathMeasure: Severity of COVID-19 infection Time: at 24 months
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports